Goldman Sachs
PGNX

Goldman Sachs’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Goldman Sachs’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-338,888
Closed -$1.29M – 5636
2020
Q1 		$1.29M Buy
338,888
+38,120
+13% +$164K ﹤0.01% 3581
2019
Q4 		$1.53M Buy
300,768
+121,182
+67% +$641K ﹤0.01% 3843
2019
Q3 		$908K Buy
179,586
+68,231
+61% +$340K ﹤0.01% 4095
2019
Q2 		$687K Sell
111,355
-224,374
-67% -$1.08M ﹤0.01% 4231
2019
Q1 		$1.56M Buy
335,729
+39,968
+14% +$181K ﹤0.01% 3792
2018
Q4 		$1.24M Sell
295,761
-21,980
-7% -$112K ﹤0.01% 3845
2018
Q3 		$1.99M Sell
317,741
-21,269
-6% -$163K ﹤0.01% 3612
2018
Q2 		$2.73M Buy
339,010
+115,003
+51% +$878K ﹤0.01% 3411
2018
Q1 		$1.67M Sell
224,007
-23,963
-10% -$159K ﹤0.01% 3720
2017
Q4 		$1.48M Buy
247,970
+32,242
+15% +$196K ﹤0.01% 4027
2017
Q3 		$1.59M Sell
215,728
-97,278
-31% -$618K ﹤0.01% 4170
2017
Q2 		$2.13M Sell
313,006
-521,736
-63% -$3.85M ﹤0.01% 3790
2017
Q1 		$7.88M Buy
834,742
+563,534
+208% +$5.62M ﹤0.01% 2568
2016
Q4 		$2.34M Sell
271,208
-669,130
-71% -$4.95M ﹤0.01% 3706
2016
Q3 		$5.95M Buy
940,338
+889,454
+1,748% +$5.38M ﹤0.01% 2900
2016
Q2 		$215K Buy
50,884
+30,299
+147% +$146K ﹤0.01% 5641
2016
Q1 		$90K Sell
20,585
-124,865
-86% -$556K ﹤0.01% 6117
2015
Q4 		$891K Sell
145,450
-37,460
-20% -$246K ﹤0.01% 4413
2015
Q3 		$1.05M Buy
182,910
+20,457
+13% +$157K ﹤0.01% 4433
2015
Q2 		$1.21M Buy
162,453
+78,216
+93% +$473K ﹤0.01% 4361
2015
Q1 		$504K Buy
84,237
+25,617
+44% +$161K ﹤0.01% 5121
2014
Q4 		$443K Buy
58,620
+9,696
+20% +$58K ﹤0.01% 5397
2014
Q3 		$254K Sell
48,924
-10,334
-17% -$51.5K ﹤0.01% 5929
2014
Q2 		$255K Sell
59,258
-8,352
-12% -$31.9K ﹤0.01% 6006
2014
Q1 		$277K Sell
67,610
-46,110
-41% -$236K ﹤0.01% 5805
2013
Q4 		$606K Buy
113,720
+27,636
+32% +$122K ﹤0.01% 5151
2013
Q3 		$432K Sell
86,084
-7,268
-8% -$39.4K ﹤0.01% 5263
2013
Q2 		$416K Buy
+93,352
New +$419K ﹤0.01% 5084

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Goldman Sachs's PGNX Position: Q2 2020 in Review

Goldman Sachs sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 338,888 shares — an estimated $1.29M sold.

Goldman Sachs first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $7.88M in Q1 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Goldman Sachs reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Goldman Sachs sold 338,888 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $1.29M.
  • Goldman Sachs first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
  • Goldman Sachs's Progenics Pharmaceuticals Inc position peaked at $7.88M in Q1 2017.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Goldman Sachs's 13F filing for Q2 2020, filed 12 Aug 2020.